Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Translational Medicine
Published in: Journal of Translational Medicine 1/2005

Open Access 01-12-2005 | Research

Protein kinase activity is associated with CD63 in melanoma cells

Authors: Joji Iida, Amy PN Skubitz, James B McCarthy, Keith M Skubitz

Published in: Journal of Translational Medicine | Issue 1/2005

Login to get access

Abstract

Background

The tetraspan protein CD63, originally described as a stage-specific melanoma antigen but also present in a number of normal cells, regulates melanoma cell growth in nude mice, motility in serum containing media, and adhesion to several extracellular matrix proteins. CD63 has been reported to associate with β1 and β2 integrins, but the mechanism of signal transduction by CD63 is not clear. This study examined whether CD63 is associated with protein kinase and can transmit signals in melanoma cells.

Methods

Immunoprecipitation and radiolabeling were used to test for association of protein kinase activity with CD63. Adhesion of cells to monoclonal antibodies immobilized to microtiter plates was used to examine the ability of CD63 to transmit signals.

Results

CD63 was capable of transmitting a signal in melanoma cells that required extracellular calcium. In the absence of extracellular calcium at the time of binding to the CD63 mAb, the cell was no longer responsive to stimulation by CD63. Immunoprecipitation studies demonstrated protein kinase activity associated with CD63, and phosphoamino acid analysis revealed that most of this protein kinase activity was due to serine kinase activity.

Conclusion

The current study suggests that serine protein kinase activity associated with CD63 may play a role in signaling by CD63 in melanoma cells.
Appendix
Available only for authorised users
Literature
1.
Metzelaar MJ, Wijngaard PLJ, Peters PJ, Sixma JJ, Nieuwenhuis HK, Clevers HC: CD63 Antigen. Journal of Biological Chemistry. 1991, 266: 3239-3245.PubMed
2.
Azorsa DO, Hyman JA, Hildreth JEK: CD63/Pltgp40: A platelet activation antigen identical to the stage-specific, melanoma-associated antigen ME491. Blood. 1991, 78: 280-284.PubMed
3.
Hotta H, Ross AH, Huebner K, Isobe M, Wendeborn S, Chao MV, Ricciardi RP, Tsujimoto Y, Croce CM, Koprowski H: Molecular cloning and characterization of an antigen associated with early stages of melanoma tumor progression. Cancer Research. 1988, 48: 2955-2962.PubMed
4.
Hotta H, Miyamoto H, Hara I, Takahashi N, Homma M: Genomic structure of the ME491/CD63 antigen gene and functional analysis of the 5'-flanking regulatory sequences. Biochemical and Biophysical Research Communications. 1992, 185: 436-442. 10.1016/S0006-291X(05)81004-6.CrossRefPubMed
5.
Nishikata H, Oliver C, Mergenhagen SE, Siraganian RP: The rat mast cell antigen AD1 (homologue to human CD63 or melanoma antigen ME491) is expressed in other cells in culture. Journal of Immunology. 1992, 149: 862-870.
6.
Kondoh M, Ueda M, Ichihashi M, Mishima Y: Decreased expression of human melanoma-associated antigen ME491 along the progression of melanoma pre-canceroses to invasive and metastatic melanomas. Melanoma Res. 1993, 3: 241-245.PubMed
7.
Atkinson B, Ernst CS, Ghrist BF, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G, Steplewski Z, Koprowski H: Monoclonal antibody to a highly glycosylated protein reacts in fixed tissue with melanoma and other tumors. Hybridoma. 1985, 4: 243-255.CrossRefPubMed
8.
Sikora LK, Pinto A, Demetrick DJ, Dixon WT, Urbanski SJ, Temple W, Jerry LM: Characterization of a novel neuroglandular antigen (NGA) expressed on abnormal human melanocytes. Int J Cancer. 1987, 39: 138-145.CrossRefPubMed
9.
Metzelaar MJ, Schuurman HJ, Heijnen HFG, Sixma JJ, Nieuwenhuis HK: Biochemical and immunohistochemical characteristics of CD62 and CD63 monoclonal antibodies. Virchows Archiv (Berlin). 1991, 61: 269-277.CrossRef
10.
Nieuwenhuis HK, van Oosterhout JJG, Rozemuller E, van Iwaarden F, Sixma JJ: Studies with a monoclonal antibody against activated platelets: Evidence that a secreted 53,000-molecular weight lysosome-like granule protein is exposed on the surface of activated platelets in the circulation. Blood. 1987, 70: 838-845.PubMed
11.
Knol EF, Mul FPJ, Jansen H, Calafat J, Roos D: Monitoring human basophil activation via CD63 monoclonal antibody 435. Journal of Allergy and Clinical Immunology. 1991, 88: 328-338. 10.1016/0091-6749(91)90094-5.CrossRefPubMed
12.
Peters PJ, Borst J, Oorschot V, Fukuda M, Krahenbuhl O, Tschopp J, Slot JW, Geuze HJ: Cytotoxic T lymphocyte granules are secretory lysosomes, containing both perforin and granzymes. Journal of Experimental Medicine. 1991, 173: 1099-1109. 10.1084/jem.173.5.1099.CrossRefPubMed
13.
Kuijpers TW, Tool ATJ, van der Schoot EC, Ginsel LA, Onderwater JJM, Roos DVAJ: Membrane surface antigen expression on neutrophils: A reappraisal of the use of surface markers for neutrophils activation. Blood. 1991, 78: 1105-1111.PubMed
14.
Horejsí V, Vlcek C: Novel structurally distinct family of leucocyte surface glycoproteins including CD9, CD37, CD53, and CD63. FEBS Letters. 1991, 288: 1-4. 10.1016/0014-5793(91)80988-F.CrossRefPubMed
15.
Skubitz KM, Campbell KD, Iida J, Skubitz APN: CD63 associates with tyrosine kinase activity and CD11/CD18, and transmits an activation signal in neutrophils. Journal of Immunology. 1996, 157: 3617-3626.
16.
Vischer UM, Wagner DD: CD63 is a component of Weibel-Palade bodies of human endothelial cells. Blood. 1993, 82: 1184-1191.PubMed
17.
Toothill VJ, van Mourik JA, Niewenhuis HK, Metzelaar MJ, Pearson JD: Characterization of the enhanced adhesion of neutrophil leukocytes to thrombin-stimulated endothelial cells. Journal of Immunology. 1990, 145: 283-291.
18.
Nishibori M, Cham B, McNicol A, Shalev A, Jain N, Gerrard JM: The protein CD63 is in platelet dense granules, is deficient in a patient with Hermansky-Pudlak syndrome, and appears identical to granulophysin. Journal of Clinical Investigation. 1993, 91: 1775-1782.PubMedCentralCrossRefPubMed
19.
Hotta H, Hara I, Miyamoto H, Homma M: Overexpression of the human melanoma-associated antigen ME491 partially suppresses in vivo malignant phenotypes of H-ras-transformed NIH3T3 cells in athymic nude mice. Melanoma Res. 1991, 1: 125-132.CrossRefPubMed
20.
Radford KJ, Mallesch J, Hersey P: Suppression of human melanoma cell growth and metastasis by the melanoma-associated antigen CD63 (ME491). Int J Cancer. 1995, 62: 631-635.CrossRefPubMed
21.
Radford KJ, Thorne RF, Hersey P: Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. J Immunol. 1997, 158: 3353-3358.PubMed
22.
Jang HI, Lee H: A decrease in the expression of CD63 tetraspanin protein elevates invasive potential of human melanoma cells. Exp Mol Med. 2003, 35: 317-323.CrossRefPubMed
23.
Azorsa DO, Hildreth JEK: CD63 cluster workshop report. Leucocyte Typing V. 1995, , Oxford University Press, Oxford, England, 1352-
24.
Fukuda M: Lysosomal membrane glycoproteins. Journal of Biological Chemistry. 1991, 266: 21327-21330.PubMed
25.
Imai T, Fukudome K, Takagi S, Nagira M, Furuse M, Fukuhara N, Nishimura M, Hinuma Y, Yoshie O: CD33 antigen recognized by monoclonal antibodies inhibitory to human T cell leukemia virus type 1-induced syncytium formation is a member of a new family of transmembrane proteins including CD9, CD37, CD53, and CD63. Journal of Immunology. 1992, 149: 2879-2886.
26.
Fidler IJ: Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev. 1986, 5: 29-49. 10.1007/BF00049529.CrossRefPubMed
27.
Skubitz KMCKDSAPN: Analysis of the Myeloid Panel of Monoclonal Antibodies by Immunoprecipitation, Immunoblotting, and Flow Cytometry. Leukocyte Typing V. Edited by: S. Schlossman . 1995, Oxford, Oxford University Press, 1071-1074.
28.
Bumol TF, Reisfeld RA: Unique glycoprotein-proteoglycan complex defined by monoclonal antibody on human melanoma cells. Proc Natl Acad Sci U S A. 1982, 79: 1245-1249.PubMedCentralCrossRefPubMed
29.
Iida J, Meijne AM, Spiro RC, Roos E, Furcht LT, McCarthy JB: Spreading and focal contact formation of human melanoma cells in response to the stimulation of both melanoma-associated proteoglycan (NG2) and alpha 4 beta 1 integrin. Cancer Res. 1995, 55: 2177-2185.PubMed
30.
Skubitz KM, Snook RWII: Monoclonal antibodies that recognize lacto-N-fucopenatose III (CD15) react with adhesion-promoting glycoprotein family (LFA-1/HMAC-1/GP 150,95) and CR1 on human neutrophils. Journal of Immunology. 1987, 139: 1631-1639.
31.
Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970, 227: 680-685. 10.1038/227680a0.CrossRefPubMed
32.
Munoz G, Marshall SH: An alternative method for a fast separation of phosphotyrosine. Anal Biochem. 1990, 190: 233-237. 10.1016/0003-2697(90)90185-C.CrossRefPubMed
33.
Skubitz KM, Goueli SA: CD31 (PECAM-1), CDw32 (Fc gamma RII), and anti-HLA class I monoclonal antibodies recognize phosphotyrosine-containing proteins on the surface of human neutrophils. J Immunol. 1994, 152: 5902-5911.PubMed
34.
Herbert JM, Augereau JM, Gleye J, Maffrand JP: Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990, 172: 993-999. 10.1016/0006-291X(90)91544-3.CrossRefPubMed
35.
Skubitz KM, Hammerschmidt DE: Corticosteroids reversibly inhibit chemotactic peptide-receptor binding and granulocyte response, yet allow desensitization and receptor down- regulation. Blood. 1986, 68: 830-836.PubMed
36.
O'Flaherty JT, Kreutzer DL, Showell HS, Becker EL, Ward PA: Desensitization of the neutrophil aggregation response to chemotactic factors. Am J Pathol. 1978, 93: 693-706.PubMedCentralPubMed
37.
Lagaudriere-Gesbert C, Le Naour F, Lebel-Binay S, Billard M, Lemichez E, Boquet P, Boucheix C, Conjeaud H, Rubinstein E: Functional analysis of four tetraspans, CD9, CD53, CD81, and CD82, suggests a common role in costimulation, cell adhesion, and migration: only CD9 upregulates HB-EGF activity. Cell Immunol. 1997, 182: 105-112. 10.1006/cimm.1997.1223.CrossRefPubMed
38.
Lazo PA, Cuevas L, Gutierrez del Arroyo A, Orue E: Ligation of CD53/OX44, a tetraspan antigen, induces homotypic adhesion mediated by specific cell-cell interactions. Cell Immunol. 1997, 178: 132-140. 10.1006/cimm.1997.1139.CrossRefPubMed
39.
Masellis-Smith A, Jensen GS, Seehafer JG, Slupsky JR, Shaw AR: Anti-CD9 monoclonal antibodies induce homotypic adhesion of pre-B cell lines by a novel mechanism. J Immunol. 1990, 144: 1607-1613.PubMed
40.
Eisenmann KM, McCarthy JB, Simpson MA, Keely PJ, Guan JL, Tachibana K, Lim L, Manser E, Furcht LT, Iida J: Melanoma chondroitin sulphate proteoglycan regulates cell spreading through Cdc42, Ack-1 and p130cas. Nat Cell Biol. 1999, 1: 507-513. 10.1038/70302.CrossRefPubMed
41.
Israels SJ, McMillan-Ward EM: CD63 modulates spreading and tyrosine phosphorylation of platelets on immobilized fibrinogen. Thromb Haemost. 2005, 93: 311-318.PubMed
42.
Berditchevski F, Bazzoni G, Hemler ME: Specific association of CD63 with the VLA-3 and VLA-6 integrins. Journal of Biological Chemistry. 1995, 270: 17784-17790. 10.1074/jbc.270.30.17784.CrossRefPubMed
43.
Berditchevski F, Tolias KF, Wong K, Carpenter CL, Hemler ME: A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J Biol Chem. 1997, 272: 2595-2598. 10.1074/jbc.272.46.29174.CrossRefPubMed
44.
Berditchevski F, Odintsova E: Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol. 1999, 146: 477-492. 10.1083/jcb.146.2.477.PubMedCentralCrossRefPubMed
45.
Radford KJ, Thorne RF, Hersey P: CD63 associates with transmembrane 4 superfamily members, CD9 and CD81, and with b1 integrins in human melanoma. Biochemical and Biophysical Research Communications. 1996, 222: 13-18. 10.1006/bbrc.1996.0690.CrossRefPubMed
Metadata
Title
Protein kinase activity is associated with CD63 in melanoma cells
Authors
Joji Iida
Amy PN Skubitz
James B McCarthy
Keith M Skubitz
Publication date
01-12-2005
Publisher
BioMed Central
Published in
Journal of Translational Medicine / Issue 1/2005
Electronic ISSN: 1479-5876
DOI
https://doi.org/10.1186/1479-5876-3-42

Other articles of this Issue 1/2005

Journal of Translational Medicine 1/2005 Go to the issue

Research

Predictors of primary breast cancers responsiveness to preoperative Epirubicin/Cyclophosphamide-based chemotherapy: translation of microarray data into clinically useful predictive signatures

Research

In vitro and in vivo evaluation of NCX 4040 cytotoxic activity in human colon cancer cell lines

Research

Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY43-9006 and mTOR inhibitor Rapamycin

Research

Delayed polarization of mononuclear phagocyte transcriptional program by type I interferon isoforms

Research

The natural history of EGFR and EGFRvIII in glioblastoma patients

Research

CD34+ cells cultured in stem cell factor and interleukin-2 generate CD56+ cells with antiproliferative effects on tumor cell lines
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits